Anti-obesity Drugs Market is estimated to grow at a CAGR of ~21.1%, till 2035, claims Roots Analysis

The anti-obesity drugs, also known as weight loss drugs, encompass a range of pharmaceutical treatments designed to assist individuals in managing obesity and related conditions. They provide healthcare professionals with valuable tools to complement lifestyle interventions, such as diet and exercise. Further, these drugs play a critical role in enhancing weight loss outcomes, particularly for patients with significant obesity-related comorbidities. Weight loss drugs also contribute to improved quality of life and can lead to reduced healthcare costs by preventing obesity-related complications. Advancements in drug formulation and delivery systems, along with the integration of novel compounds have led to the emergence of more effective and safer anti-obesity medications. Additionally, the surge in telehealth services and digital therapeutics applications is facilitating better patient engagement and adherence to treatment regimens.

For detailed information:

Email: [email protected]

Visit: https://www.rootsanalysis.com/reports/anti-obesity-drugs-market.html

Anti-obesity Drugs Market Size

According to Roots Analysis, the global anti-obesity drugs market is estimated to be USD 104.9 billion by 2035. It is worth mentioning that anti-obesity drugs market growth is driven by several factors, such as increased prevalence of obesity, rising awareness amongst patients and regulatory support. This motivates drug developers to invest in research and development, enabling them to discover weight loss drugs having enhanced safety and efficacy.

In terms of active compound used, currently, majority share of the global anti-obesity drugs market is likely to be captured by semaglutide, owing to the greater efficacy of drugs developed by utilizing this active compound. Further, amongst the route of administration segment, parenteral route of administration is anticipated to capture majority of the global anti-obesity drugs market in 2035.

Anti-obesity Drugs Market: Competitive Landscape

The current approved anti-obesity drugs market landscape comprises of around 225 anti-obesity drugs developed by more than 120 drug developers, worldwide. Notably, around 55% of the drug developers are headquartered in North America, followed by Asia-Pacific and Rest of the World. Within North America, majority of players are based in the US, whereas, within Europe, Denmark emerged as the hub for drug developers engaged in this domain. It is noteworthy that in response to the increasing demand for these anti-obesity drugs, the companies operating in this domain have undertaken several strategic initiatives in order to expand their existing capabilities / drug portfolios. Further, the drug developers landscape is fragmented, featuring a mix of both established companies as well as emerging start-ups.

Big Pharma Initiatives Undertaken within the Anti-obesity Drugs Market

Over the years, various big pharmaceutical companies engaged in the weight loss drugs domain have marked their presence in the anti-obesity drugs market. These players have undertaken a number of initiatives in order to expand their respective drug portfolios and augment their capabilities. Notably, a sizeable proportion (70%) of big pharma players have entered in partnerships to expand their current anti-obesity drug portfolio; followed by players (18%) undertaking expansion initiatives.

Leading Companies in Anti-obesity Drugs Market

Examples of obesity drug companies engaged in this domain (which have also been profiled in this report, arranged in alphabetical order) include Adocia, AstraZeneca, Boehringer Ingelheim, CinFina Pharma, Eli Lilly, Gmax Biopharma, Hanmi Pharm, Jiangsu Hengrui Pharmaceuticals, Kallyope, Novo Nordisk, PegBio, Pfizer? QL Biopharm, Regeneron, Roche, Sciwind Biosciences, Viking Therapeutics and Zealand Pharma. This market report includes an easily searchable excel database of all the pharmaceutical companies engaged in the development of anti-obesity drugs.

All your Questions Related to Anti-obesity Drugs Market Answered in this Report

The Anti-obesity Drugs Market, till 2035 report features an extensive study of the current market landscape, market size and future opportunities associated with the weight loss drugs domain, during the given forecast period. Further, the anti-obesity drugs market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the healthcare industry. The report answers many key questions related to this market. Click on the below link to know more about this emerging area of research.

https://www.rootsanalysis.com/reports/anti-obesity-drugs-market.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.